Corticorelin-Related Trial NCT05703425 Recruiting for Phase 2 Study

A clinical trial update dated July 9, 2026 reports on a study relevant to corticorelin, an approved compound also known as CRH. The trial, titled "The Effect of Sulfasalazine on CRH Levels in Pregnant Women," is registered under identifier NCT05703425. According to ClinicalTrials.gov, the study is currently in Phase 2 and its status is listed as recruiting. No results have been posted for this trial as of the date of this update. The study title indicates an investigation into sulfasalazine and its effect on CRH levels in pregnant women, but no outcome data, efficacy claims, or safety findings are included in this update. The recruiting status means the trial is actively enrolling participants and has not yet reached a stage where conclusions can be drawn. Readers should note that this brief reflects only the status and phase information available at this time. For additional context on corticorelin, including its approved regulatory status and general background, readers can consult the compound overview.